Chris Claxton
VP Investor Relations & Strategic Marketing
Chris has over twenty years experience in investor relations, corporate development and strategic marketing in the fields of clinical diagnostics, medical devices, lab instrumentation, molecular biology, and pharmaceutical development. Chris joins Owlstone from Horizon Discovery where from 2012 he developed and led the global marketing team before becoming the investor relations officer in early 2016, while helping drive corporate development and corporate communication activities across the organisation. Previously Chris was Market Segment Manager at SAFC (a division of Sigma Aldrich, now part of Merck), Marketing Director at ArcticDX Inc. and Associate Director, Strategic Marketing at Luminex Molecular Diagnostics. Chris, a UK/Canadian dual citizen, has a Master of Science degree and an MBA from the University of Toronto.